SG-55 | AKR1C3 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $70.00 | ||
| 25 mg | $250.00 |
SG-55 is a noncompetitive AKR1C3 inhibitor (IC50 = 5 nM) with high selectivity over other isoforms. It synergized with Osimertinib in EGFR mutant cancer cells to suppress cell proliferation, clonogenicity, and survival. SG-55 resensitized PC-9/OR triple mutant NSCLC cells to Osimertinib treatment. Active in vivo.
References/Citations:
- Guo et al. (2026), Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer; J. Med. Chem. 69 6399
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SG-55 is a noncompetitive AKR1C3 inhibitor (IC50 = 5 nM) with high selectivity over other isoforms. It synergized with Osimertinib in EGFR mutant cancer cells to suppress cell proliferation, clonogenicity, and survival. SG-55 resensitized PC-9/OR triple mutant NSCLC cells to Osimertinib treatment. Active in vivo.
References/Citations:
- Guo et al. (2026), Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer; J. Med. Chem. 69 6399
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass